GERMANTOWN, Md.--(EON: Enhanced Online News)--Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, today announced the launch of a new web-based marketplace to further affirm the Company as the global leader in e-commerce for hemorrhagic fever research and clinical testing.
“This expansion of our corporate website to include e-commerce capability will enable researchers and our distribution partners to easily secure these high-performance, critical reagents and materials to address Ebola, Lassa and other hemorrhagic fevers”
At launch, the Zalgen product list includes nine test kits for Ebola and Lassa fevers in rapid diagnostic test (RDT) and ELISA test formats. The intended use of the RDTs is for the presumptive detection of Ebola and Lassa fever viruses in individuals with signs and symptoms of virus infection in conjunction with epidemiological risk factors (including geographic locations with high prevalence of infection). Additionally, the site includes Lassa virus antibodies specifically for use in various testing formats, including Western blot, ELISA, Immunoprecipitation and Immunofluorescence.
The hemorrhagic fever products licensed to and marketed by Zalgen have been developed by Tulane University in cooperation with additional members of the Viral Hemorrhagic Fever Consortium (VHFC). The VHFC is a collaboration of academic and industry members headed by Tulane University, including Autoimmune Technologies LLC, The Scripps Research Institute and the University of Texas Medical Branch at Galveston, as well as other collaborators in West Africa.
“This expansion of our corporate website to include e-commerce capability will enable researchers and our distribution partners to easily secure these high-performance, critical reagents and materials to address Ebola, Lassa and other hemorrhagic fevers,” said Luis M Branco, Ph.D., Managing Director and Co-Founder of Zalgen Labs. “We will continue to expand the e-commerce site to include additional tropical diseases.”
Development of the Zalgen kits and reagents was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) along with additional support provided by The Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation.
About Zalgen Labs
Zalgen Labs is a biotechnology and diagnostics company with headquarters in Germantown, Md., and an advanced diagnostic product development center in Aurora, Colo. The company specializes in the design and production of superior biological molecules critical for the development and commercialization of immunotherapeutics, novel vaccines, and reliable, rapid and affordable diagnostic platforms targeting neglected and underrepresented human infectious diseases. For more information, visit www.zalgenlabs.com.
About the Viral Hemorrhagic Fever Consortium
The Viral Hemorrhagic Fever Consortium was established in 2010 as a result of several multi-year grants and contracts awarded to Tulane University by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to support Tulane’s ongoing efforts to treat and prevent Lassa fever. For more information, visit www.vhfc.org.